Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group

Uveitis occurred in a substantial proportion of AIDS patients receiving rifabutin, 600 mg daily, together with clarithromycin and ethambutol for treatment of Mycobacterium avium complex bacteremia. A case-control study was undertaken to examine potential risk factors for developing uveitis. Of eight...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1998-01, Vol.177 (1), p.252
Main Authors: Shafran, S D, Singer, J, Zarowny, D P, Deschênes, J, Phillips, P, Turgeon, F, Aoki, F Y, Toma, E, Miller, M, Duperval, R, Lemieux, C, Schlech, 3rd, W F
Format: Article
Language:English
Subjects:
Adult
AIDS-Related Opportunistic Infections - drug therapy
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibiotics, Antitubercular - administration & dosage
Antibiotics, Antitubercular - adverse effects
Antibiotics, Antitubercular - therapeutic use
Antitubercular Agents - administration & dosage
Antitubercular Agents - adverse effects
Antitubercular Agents - therapeutic use
Bacteremia - complications
Clarithromycin - administration & dosage
Clarithromycin - adverse effects
Clarithromycin - therapeutic use
Drug Therapy, Combination
Ethambutol - administration & dosage
Ethambutol - adverse effects
Ethambutol - therapeutic use
Female
Humans
Incidence
Male
Middle Aged
Multivariate Analysis
Mycobacterium avium-intracellulare Infection - drug therapy
Rifabutin - administration & dosage
Rifabutin - adverse effects
Rifabutin - therapeutic use
Risk Factors
Uveitis - chemically induced
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Uveitis occurred in a substantial proportion of AIDS patients receiving rifabutin, 600 mg daily, together with clarithromycin and ethambutol for treatment of Mycobacterium avium complex bacteremia. A case-control study was undertaken to examine potential risk factors for developing uveitis. Of eight parameters examined, only baseline body weight predicted the development of uveitis by both univariate and multivariate analyses (P = .001). The incidence of uveitis was 14% in patients weighing >65 kg, 45% in patients between 55 and 65 kg, and 64% in patients
ISSN:0022-1899